Applying complement therapeutics to rare diseases

Clinical Immunology

Volumn 161, Issue 2, 2015, Pages 225-240

  Reis, Edimara S ^a   Mastellos, Dimitrios C ^b   Yancopoulou, Despina ^c   Risitano, Antonio M ^d   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c Amyndas Pharmaceuticals   (Greece)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autoimmune diseases; C1 inhibitor; Complement; Compstatin; Eculizumab; Orphan drugs; Rare diseases

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR D; ECULIZUMAB; MONOCLONAL ANTIBODY;

AGE RELATED MACULAR DEGENERATION; ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; C3 GLOMERULOPATHY; COMPLEMENT SYSTEM; DERMATOMYOSITIS; DISEASE EXACERBATION; GLOMERULOPATHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOREGULATION; INFLAMMATION; MOTOR NEUROPATHY; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RARE DISEASE; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; ANGIOEDEMAS, HEREDITARY; BIOLOGICAL MODEL; COMPLEMENT ACTIVATION; DRUG EFFECTS; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; RARE DISEASES; SIGNAL TRANSDUCTION;

ANGIOEDEMAS, HEREDITARY; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MODELS, IMMUNOLOGICAL; RARE DISEASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84942694244     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.08.009     Document Type: Review

References (140)

1. Zarkadis I.K., Mastellos D., Lambris J.D. Phylogenetic aspects of the complement system. Dev. Comp. Immunol. 2001, 25:745-762.
2. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
3. Kemper C., Kohl J. Novel roles for complement receptors in T cell regulation and beyond. Mol. Immunol. 2013, 56:181-190.
4. Kolev M., Le F.G., Kemper C. Complement-tapping into new sites and effector systems. Nat. Rev. Immunol. 2014, 14:811-820.
5. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600-2608.
6. Merle N.S., Church S.E., Fremeaux-Bacchi V., Roumenina L.T. Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol. 2015, 6:262.
7. Morgan B.P. The membrane attack complex as an inflammatory trigger. Immunobiology 2015.
8. Kim D.D., Song W.C. Membrane complement regulatory proteins. Clin. Immunol. 2006, 118:127-136.
9. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831-3838.
10. Liszewski K., Atkinson J.P. Complement regulators in human disease: lessons from modern genetics. J. Intern. Med. 2015, 277:294-305.
11. Feussner A., Kalina U., Hofmann P., Machnig T., Henkel G. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion 2014, 54:2566-2573.
12. Vo A.A., Zeevi A., Choi J., Cisneros K., Toyoda M., Kahwaji J., Peng A., Villicana R., Puliyanda D., Reinsmoen N., Haas M., Jordan S.C. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 2015, 99:299-308.
13. Hofstra J.J., Kleine Budde I., van Twuyver E., Choi G., Levi M., Leebeek F.W., de Monchy J.G., Ypma P.F., Keizer R.J., Huitema A.D., Strengers P.F. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin. Immunol. 2012, 142:280-290.
14. Levy M., Mealy M.A. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm. 2014, 1:e5.
15. Hack C.E., Relan A., van Amersfoort E.S., Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012, 67:123-130.
16. van Doorn M.B., Burggraaf J., van Dam T., Eerenberg A., Levi M., Hack C.E., Schoemaker R.C., Cohen A.F., Nuijens J. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol. 2005, 116:876-883.
17. Kelemen Z., Moldovan D., Mihaly E., Visy B., Szeplaki G., Csuka D., Fust G., Farkas H., Varga L. Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema. Clin. Immunol. 2010, 134:354-358.
18. Caccia S., Suffritti C., Cicardi M. Pathophysiology of hereditary angioedema. Pediatr. Allergy Immunol. Pulmonol. 2014, 27:159-163.
19. Bernstein J.A. HAE update: epidemiology and burden of disease. Allergy Asthma Proc. 2013, 34:3-6.
20. Truedsson L. Classical pathway deficiencies - a short analytical review. Mol. Immunol. 2015.
21. Keck T. Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis. Pancreatology 2001, 1:656-661.
22. Berentsen S., Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Biomed Res. Int. 2015, 2015:363278.
23. Swiecicki P.L., Hegerova L.T., Gertz M.A. Cold agglutinin disease. Blood 2013, 122:1114-1121.
24. Shi J., Rose E.L., Singh A., Hussain S., Stagliano N.E., Parry G.C., Panicker S. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014, 123:4015-4022.
25. Matsushita M., Endo Y., Fujita T. Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch. Immunol. Ther. Exp. (Warsz) 2013, 61:273-283.
26. Olszowski T., Poziomkowska-Gesicka I., Jensenius J.C., Adler G. Lectin pathway of complement activation in a Polish woman with MASP-2 deficiency. Immunobiology 2014, 219:261-262.
27. Stengaard-Pedersen K., Thiel S., Gadjeva M., Moller-Kristensen M., Sorensen R., Jensen L.T., Sjoholm A.G., Fugger L., Jensenius J.C. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003, 349:554-560.
28. Noris M., Mescia F., Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 2012, 8:622-633.
29. Johannes L., Romer W. Shiga toxins-from cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8:105-116.
30. Ren G., Hack B.K., Minto A.W., Cunningham P.N., Alexander J.J., Haas M., Quigg R.J. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin. Immunol. 2002, 103:43-53.
31. Riedl M., Fakhouri F., Le Q.M., Noone D.G., Jungraithmayr T.C., Fremeaux-Bacchi V., Licht C. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin. Thromb. Hemost. 2014, 40:444-464.
32. Heitzeneder S., Seidel M., Forster-Waldl E., Heitger A. Mannan-binding lectin deficiency - good news, bad news, doesn't matter?. Clin. Immunol. 2012, 143:22-38.
33. Licht C., Greenbaum L.A., Muus P., Babu S., Bedrosian C.L., Cohen D.J., Delmas Y., Douglas K., Furman R.R., Gaber O.A., Goodship T., Herthelius M., Hourmant M., Legendre C.M., Remuzzi G., Sheerin N., Trivelli A., Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015, 87:1061-1073.
34. Volanakis J.E., Narayana S.V. Complement factor D, a novel serine protease. Protein Sci. 1996, 5:553-564.
35. Biesma D.H., Hannema A.J., van Velzen-Blad H., Mulder L., van Zwieten R., Kluijt I., Roos D. A family with complement factor D deficiency. J. Clin. Invest. 2001, 108:233-240.
36. Sprong T., Roos D., Weemaes C., Neeleman C., Geesing C.L., Mollnes T.E., van Deuren M. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006, 107:4865-4870.
37. Stanton C.M., Yates J.R., den Hollander A.I., Seddon J.M., Swaroop A., Stambolian D., Fauser S., Hoyng C., Yu Y., Atsuhiro K., Branham K., Othman M., Chen W., Kortvely E., Chalmers K., Hayward C., Moore A.T., Dhillon B., Ueffing M., Wright A.F. Complement factor D in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2011, 52:8828-8834.
38. Katschke K.J., Wu P., Ganesan R., Kelley R.F., Mathieu M.A., Hass P.E., Murray J., Kirchhofer D., Wiesmann C., van Lookeren C.M. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 2012, 287:12886-12892.
39. Morgan B.P., Thanassi J., Podos S., Phadke A., Gadhachanda V., Pais G., Hashimoto A., Wang Q., Chen D., Wang X., Agarwal A., Deshpande M., Huang Y., Wiles J., Huang M. Novel small molecule inhibitors targeting complement factor D for therapy of paroxysmal nocturnal hemoglobinuria. Blood 2014, 124.
40. Bora N.S., Matta B., Lyzogubov V.V., Bora P.S. Relationship between the complement system, risk factors and prediction models in age-related macular degeneration. Mol. Immunol. 2015, 63:176-183.
41. Loyet K.M., Good J., Davancaze T., Sturgeon L., Wang X., Yang J., Le K.N., Wong M., Hass P.E., van Lookeren C.M., Haughney P.C., Morimoto A., mico-Beyer L.A., DeForge L.E. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J. Pharmacol. Exp. Ther. 2014, 351:527-537.
42. Do D.V., Pieramici D.J., van Lookeren C.M., Beres T., Friesenhahn M., Zhang Y., Strauss E.C. A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina 2014, 34:313-320.
43. Yehoshua Z., de Amorin Garcia Filho C.A., Nunes R.P., Gregori G., Penha F.M., Moshfeghi A.A., Zhang K., Sadda S., Feuer W., Rosenfeld P.J. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014, 121:693-701.
44. Garcia Filho C.A., Yehoshua Z., Gregori G., Nunes R.P., Penha F.M., Moshfeghi A.A., Zhang K., Feuer W., Rosenfeld P.J. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg. Lasers Imaging Retina 2014, 45:18-31.
45. Klos A., Wende E., Wareham K.J., Monk P.N. International union of basic and clinical pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 2013, 65:500-543.
46. Wu M.C., Brennan F.H., Lynch J.P., Mantovani S., Phipps S., Wetsel R.A., Ruitenberg M.J., Taylor S.M., Woodruff T.M. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9439-9444.
47. Mueller-Ortiz S.L., Morales J.E., Wetsel R.A. The receptor for the complement C3a anaphylatoxin (C3aR) provides host protection against Listeria monocytogenes-induced apoptosis. J. Immunol. 2014, 193:1278-1289.
48. Cardone J., Le F.G., Vantourout P., Roberts A., Fuchs A., Jackson I., Suddason T., Lord G., Atkinson J.P., Cope A., Hayday A., Kemper C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat. Immunol. 2010, 11:862-871.
49. Carroll M.C., Isenman D.E. Regulation of humoral immunity by complement. Immunity 2012, 37:199-207.
50. Lachmann P.J., Smith R.A. Taking complement to the clinic-has the time finally come?. Scand. J. Immunol. 2009, 69:471-478.
51. Skattum L., Martensson U., Sjoholm A.G. Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J. Intern. Med. 1997, 242:455-464.
52. Ricklin D., Lambris J.D. Therapeutic control of complement activation at the level of the central component C3. Immunobiology 2015.
53. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 1996, 157:884-891.
54. Mastellos D.C., Yancopoulou D., Kokkinos P., Huber-Lang M., Hajishengallis G., Biglarnia A.R., Lupu F., Nilsson B., Risitano A.M., Ricklin D., Lambris J.D. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Investig. 2015, 45:423-440.
55. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013, 218:496-505.
56. Risitano A.M. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv. Exp. Med. Biol. 2013, 735:155-172.
57. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-a gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703-711.
58. Mastellos D.C., Ricklin D., Yancopoulou D., Risitano A., Lambris J.D. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert. Rev. Hematol. 2014, 7:583-598.
59. Brodsky R.A., Young N.S., Antonioli E., Risitano A.M., Schrezenmeier H., Schubert J., Gaya A., Coyle L., de C.C., Fu C.L., Maciejewski J.P., Bessler M., Kroon H.A., Rother R.P., Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 1840-1847, 111(2008).
60. Hillmen P., Muus P., Duhrsen U., Risitano A.M., Schubert J., Luzzatto L., Schrezenmeier H., Szer J., Brodsky R.A., Hill A., Socie G., Bessler M., Rollins S.A., Bell L., Rother R.P., Young N.S. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110:4123-4128.
61. Nishimura J., Yamamoto M., Hayashi S., Ohyashiki K., Ando K., Brodsky A.L., Noji H., Kitamura K., Eto T., Takahashi T., Masuko M., Matsumoto T., Wano Y., Shichishima T., Shibayama H., Hase M., Li L., Johnson K., Lazarowski A., Tamburini P., Inazawa J., Kinoshita T., Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 2014, 370:632-639.
62. Rondelli T., Risitano A.M., Peffault de Latour R., Sica M., Peruzzi B., Ricci P., Barcellini W., Iori A.P., Boschetti C., Valle V., Fremeaux-Bacchi V., De Angioletti M., Socie G., Luzzatto L., Notaro R. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2014, 99:262-266.
63. Risitano A.M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., Ricci P., Alfinito F., Camera A., Gianfaldoni G., Amendola A., Boschetti C., Di B.E., Fratellanza G., Barbano F., Rodeghiero F., Zanella A., Iori A.P., Selleri C., Luzzatto L., Rotoli B. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094-4100.
64. Lin Z., Schmidt C.Q., Koutsogiannaki S., Ricci P., Risitano A.M., Lambris J.D., Ricklin D. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 2015.
65. Risitano A.M., Notaro R., Pascariello C., Sica M., Del V.L., Horvath C.J., Fridkis-Hareli M., Selleri C., Lindorfer M.A., Taylor R.P., Luzzatto L., Holers V.M. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119:6307-6316.
66. Schmidt C.Q., Bai H., Lin Z., Risitano A.M., Barlow P.N., Ricklin D., Lambris J.D. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 2013, 190:5712-5721.
67. Risitano A.M., Ricklin D., Huang Y., Reis E.S., Chen H., Ricci P., Lin Z., Pascariello C., Raia M., Sica M., Del V.L., Pane F., Lupu F., Notaro R., Resuello R.R., DeAngelis R.A., Lambris J.D. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123:2094-2101.
68. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151.
69. Li J.S., Jaggers J., Anderson P.A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert. Rev. Cardiovasc. Ther. 2006, 4:649-654.
70. Zhang Y., Nester C.M., Holanda D.G., Marsh H.C., Hammond R.A., Thomas L.J., Meyer N.C., Hunsicker L.G., Sethi S., Smith R.J. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J. Am. Soc. Nephrol. 2013, 24:1820-1829.
71. Fridkis-Hareli M., Storek M., Mazsaroff I., Risitano A.M., Lundberg A.S., Horvath C.J., Holers V.M. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705-4713.
72. Pickering M.C., D'Agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., Alpers C.E., Bajema I.M., Bedrosian C., Braun M., Doyle M., Fakhouri F., Fervenza F.C., Fogo A.B., Fremeaux-Bacchi V., Gale D.P., Goicoechea de Jorge E., Griffin G., Harris C.L., Holers V.M., Johnson S., Lavin P.J., Medjeral-Thomas N., Morgan B.P., Nast C.C., Noel L.H., Peters D.K., Rodriguez de Cordoba S., Servais A., Sethi S., Song W.C., Tamburini P., Thurman J.M., Zavros M., Cook H.T. C3 glomerulopathy: consensus report. Kidney Int. 2013, 84:1079-1089.
73. Sethi S., Fervenza F.C., Zhang Y., Zand L., Vrana J.A., Nasr S.H., Theis J.D., Dogan A., Smith R.J. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012, 82:465-473.
74. Servais A., Noel L.H., Roumenina L.T., Le Q.M., Ngo S., Dragon-Durey M.A., Macher M.A., Zuber J., Karras A., Provot F., Moulin B., Grunfeld J.P., Niaudet P., Lesavre P., Fremeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012, 82:454-464.
75. Bomback A.S. Eculizumab in the treatment of membranoproliferative glomerulonephritis. Nephron Clin. Pract. 2014, 128:270-276.
76. Bomback A.S., Smith R.J., Barile G.R., Zhang Y., Heher E.C., Herlitz L., Stokes M.B., Markowitz G.S., D'Agati V.D., Canetta P.A., Radhakrishnan J., Appel G.B. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 2012, 7:748-756.
77. Herlitz L.C., Bomback A.S., Markowitz G.S., Stokes M.B., Smith R.N., Colvin R.B., Appel G.B., D'Agati V.D. Pathology after eculizumab in dense deposit disease and C3 GN. J. Am. Soc. Nephrol. 2012, 23:1229-1237.
78. Zhang Y., Shao D., Ricklin D., Hilkin B.M., Nester C.M., Lambris J.D., Smith R.J. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 2015, 220:993-998.
79. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
80. Legendre C.M., Licht C., Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 369:1379-1380.
81. M. Herper, The most expensive drugs in the world, Forbes Magazine, 2010.
82. Barratt-Due A., Thorgersen E.B., Lindstad J.K., Pharo A., Lissina O., Lambris J.D., Nunn M.A., Mollnes T.E. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J. Immunol. 2011, 187:4913-4919.
83. Stromberg P. Introducing SOBI002, a small Affibody-ABD fusion protein targeting complement component C5. Aegean Conferences 2014, 82.
84. Borodovsky A., Yucius K., Sprague A., Banda N.K., Holers V.M., Vaishnaw A., Maier M., Kallanthottathil R., Charisse K., Kuchimanchi S., Manoharan M., Salant D.J., Fitzgerald K., Meyers R., Sorensen B. Aln-CC5, an investigational RNAi therapeutic targeting C5 for complement inhibition. Blood 2014, 214.
85. Bendewald M.J., Wetter D.A., Li X., Davis M.D. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch. Dermatol. 2010, 146:26-30.
86. Fardet L., Dupuy A., Gain M., Kettaneh A., Cherin P., Bachelez H., Dubertret L., Lebbe C., Morel P., Rybojad M. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009, 88:91-97.
87. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat. Rev. Rheumatol. 2010, 6:129-137.
88. Dalakas M.C. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther. Adv. Neurol. Disord. 2008, 1:157-166.
89. Dalakas M.C. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J. Clin. Immunol. 2014, 34(Suppl. 1):S120-S126.
90. Vanoni F., Jorgensen C., Parvex P., Chizzolini C., Hofer M. A difficult case of juvenile dermatomyositis complicated by thrombotic microangiopathy and purtscher-like retinopathy. Pediatr. Rheumatol. 2014, 12:275.
91. Pandit L., Asgari N., Apiwattanakul M., Palace J., Paul F., Leite M.I., Kleiter I., Chitnis T. Demographic and clinical features of neuromyelitis optica: a review. Mult. Scler. 2015, 21:845-853.
92. Papadopoulos M.C., Verkman A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11:535-544.
93. Saadoun S., Papadopoulos M.C. Role of membrane complement regulators in neuromyelitis optica. Mult. Scler. 2015.
94. Jarius S., Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 2010, 6:383-392.
95. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
96. Nytrova P., Potlukova E., Kemlink D., Woodhall M., Horakova D., Waters P., Havrdova E., Zivorova D., Vincent A., Trendelenburg M. Complement activation in patients with neuromyelitis optica. J. Neuroimmunol. 2014, 274:185-191.
97. Jones M.V., Fox-Talbot K., Levy M. Evidence for classic complement activity in neuromyelitis optica. Clin. Neuropathol. 2014, 33:251-252.
98. Papadopoulos M.C., Bennett J.L., Verkman A.S. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat. Rev. Neurol. 2014, 10:493-506.
99. Pittock S.J., Lennon V.A., McKeon A., Mandrekar J., Weinshenker B.G., Lucchinetti C.F., O'Toole O., Wingerchuk D.M. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013, 12:554-562.
100. Grob D., Brunner N., Namba T., Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008, 37:141-149.
101. Ha J.C., Richman D.P. Myasthenia gravis and related disorders: pathology and molecular pathogenesis. Biochim. Biophys. Acta 2015, 1852:651-657.
102. az-Manera J., Martinez-Hernandez E., Querol L., Klooster R., Rojas-Garcia R., Suarez-Calvet X., Munoz-Blanco J.L., Mazia C., Straasheijm K.R., Gallardo E., Juarez C., Verschuuren J.J., Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.
103. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., Xiong W.C., Lisak R.P., Tzartos S.J., Mei L. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 2012, 69:445-451.
104. Lisak R.P., Levinson A.I., Zweiman B., Kornstein M.J. Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes. J. Immunol. 1986, 137:1221-1225.
105. Sieb J.P. Myasthenia gravis: an update for the clinician. Clin. Exp. Immunol. 2014, 175:408-418.
106. Kusner L.L., Kaminski H.J., Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert. Rev. Clin. Immunol. 2008, 4:43-52.
107. Kusner L.L., Halperin J.A., Kaminski H.J. Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve 2013, 47:33-40.
108. Howard J.F., Barohn R.J., Cutter G.R., Freimer M., Juel V.C., Mozaffar T., Mellion M.L., Benatar M.G., Farrugia M.E., Wang J.J., Malhotra S.S., Kissel J.T. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013, 48:76-84.
109. van den B.B., Walgaard C., Drenthen J., Fokke C., Jacobs B.C., van Doorn P.A. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 2014, 10:469-482.
110. Winer J.B. An update in Guillain-Barre syndrome. Autoimmune Dis. 2014, 2014:793024.
111. Willison H.J., Halstead S.K., Beveridge E., Zitman F.M., Greenshields K.N., Morgan B.P., Plomp J.J. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barre syndrome. J. Neuroimmunol. 2008, 201-202:172-182.
112. Lawson V.H., Arnold W.D. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr. Dis. Treat. 2014, 10:567-576.
113. Leger J.M., Guimaraes-Costa R., Iancu F.R. The pathogenesis of multifocal motor neuropathy and an update on current management options. Ther. Adv. Neurol. Disord. 2015, 8:109-122.
114. Yuki N., Watanabe H., Nakajima T., Spath P.J. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry 2011, 82:87-91.
115. Fitzpatrick A.M., Mann C.A., Barry S., Brennan K., Overell J.R., Willison H.J. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 2011, 16:84-91.
116. Sacks S.H., Zhou W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 2012, 12:431-442.
117. Farrar C.A., Zhou W., Lin T., Sacks S.H. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006, 20:217-226.
118. Damman J., Seelen M.A., Moers C., Daha M.R., Rahmel A., Leuvenink H.G., Paul A., Pirenne J., Ploeg R.J. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation 2011, 92:163-169.
119. Farrar C.A., Asgari E., Schwaeble W.J., Sacks S.H. Which pathways trigger the role of complement in ischaemia/reperfusion injury?. Front. Immunol. 2012, 3:341.
120. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 2000, 105:1363-1371.
121. de Vries B., Kohl J., Leclercq W.K., Wolfs T.G., van Bijnen A.A., Heeringa P., Buurman W.A. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J. Immunol. 2003, 170:3883-3889.
122. Tang S., Zhou W., Sheerin N.S., Vaughan R.W., Sacks S.H. Contribution of renal secreted complement C3 to the circulating pool in humans. J. Immunol. 1999, 162:4336-4341.
123. Kwan W.H., Hashimoto D., Paz-Artal E., Ostrow K., Greter M., Raedler H., Medof M.E., Merad M., Heeger P.S. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J. Clin. Invest. 2012, 122:2234-2238.
124. Stegall M.D., Chedid M.F., Cornell L.D. The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 2012, 8:670-678.
125. Carroll M.C. The complement system in B cell regulation. Mol. Immunol. 2004, 41:141-146.
126. Stegall M.D., Diwan T., Raghavaiah S., Cornell L.D., Burns J., Dean P.G., Cosio F.G., Gandhi M.J., Kremers W., Gloor J.M. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011, 11:2405-2413.
127. Locke J.E., Magro C.M., Singer A.L., Segev D.L., Haas M., Hillel A.T., King K.E., Kraus E., Lees L.M., Melancon J.K., Stewart Z.A., Warren D.S., Zachary A.A., Montgomery R.A. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 2009, 9:231-235.
128. Chen Song S., Zhong S., Xiang Y., Li J.H., Guo H., Wang W.Y., Xiong Y.L., Li X.C., Chen Shi S., Chen X.P., Chen G. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 2011, 11:2057-2066.
129. Monk P.N., Scola A.M., Madala P., Fairlie D.P. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 2007, 152:429-448.
130. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 2011, 48:1631-1642.
131. Kallenberg C.G. Key advances in the clinical approach to ANCA-associated vasculitis. Nat. Rev. Rheumatol. 2014, 10:484-493.
132. McKinney E.F., Willcocks L.C., Broecker V., Smith K.G. The immunopathology of ANCA-associated vasculitis. Semin. Immunopathol. 2014, 36:461-478.
133. Falk R.J., Terrell R.S., Charles L.A., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4115-4119.
134. Schreiber A., Xiao H., Jennette J.C., Schneider W., Luft F.C., Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 2009, 20:289-298.
135. Xiao H., Schreiber A., Heeringa P., Falk R.J., Jennette J.C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 2007, 170:52-64.
136. Xing G.Q., Chen M., Liu G., Heeringa P., Zhang J.J., Zheng X., J E., Kallenberg C.G., Zhao M.H. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 2009, 29:282-291.
137. Gou S.J., Yuan J., Chen M., Yu F., Zhao M.H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013, 83:129-137.
138. Hao J., Meng L.Q., Xu P.C., Chen M., Zhao M.H. p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS One 2012, 7.
139. Camous L., Roumenina L., Bigot S., Brachemi S., Fremeaux-Bacchi V., Lesavre P., Halbwachs-Mecarelli L. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011, 117:1340-1349.
140. Wang C., Wang H., Hao J., Chang D.Y., Zhao M.H., Chen M. Involvement of high mobility group box 1 in the activation of C5a-primed neutrophils induced by ANCA. Clin. Immunol. 2015, 159:47-57.